Your shopping cart is currently empty

NLRP3-IN-73 (W16) is an orally bioavailable inhibitor that disrupts the assembly of the NLRP3 inflammasome, exhibiting an IC50 value of 0.18 μM for the NLRP3/IL-1β pathway.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | NLRP3-IN-73 (W16) is an orally bioavailable inhibitor that disrupts the assembly of the NLRP3 inflammasome, exhibiting an IC50 value of 0.18 μM for the NLRP3/IL-1β pathway. |
| In vitro | NLRP3-IN-73 (W16) inhibits the release of IL-1β in a dose-dependent manner in J774A.1 cells, bone marrow-derived macrophages (BMDMs), and human peripheral blood cells. |
| In vivo | NLRP3-IN-73 (W16: 7.5 mg/kg, 15 mg/kg, and 30 mg/kg, orally) exhibits significant anti-inflammatory activity in a DSS-induced ulcerative colitis model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.